Athebio AG

Athebio develops next-generation binding molecules based on designed ankyrin repeat proteins (DARPins) to help drug developers fill their pipelines with innovative drug candidates.
Our proprietary platform covers a wide range of potential therapeutic applications, reaching from immuno-oncology to viral gene therapy.
Our mission is to empower our partners, meaning that we do not strive to become a fully integrated drug developer with an own clinical pipeline, but to enable others to realize their biological ideas with a new class of custom-made binding proteins.